Abstract Library

#3303 Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors - An international double-blind, placebo-controlled randomized phase 2. Prodige 31 REMINET. A FFCD study

Introduction: Following European guidelines, patients (pts) with aggressive metastatic or locally advanced, non-resectable, duodeno-pancreatic (DP) neuroendocrine tumors (NETs), should receive systemic combination of chemotherapy until progression. Aggressive disease is defined as progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lepage C

Authors: Lepage C, Phelip J, Lievre A, Le Malicot K, Dahan L,

Keywords: clinical trial, non-resectable, duodeno-pancreatic, neuroendocrine tumor, maintenance,

#2132 Survival and Prognosis in Patients with Duodeno-Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome, affecting multiple endocrine glands. Duodeno-pancreatic neuroendocrine tumors (DP-NET) represent the most frequent type of NET in MEN1. Their prognosis and treatment strategy is debated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Modica R

Authors: Modica R, Lo Calzo F, De Cicco F, Bottiglieri F, Sciammarella C,

Keywords: neuroendocrine tumor, MEN1 syndrome, duodeno pancreatic tumor.,

#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lepage C

Authors: Lepage C, Dahan L, Legoux J, Le Malicot K, Guimbaud R,

Keywords: Duodeno-pancreatic neuroendocrine tumours, clinical trial, maintenance,

#1207 A Novel MEN1 Gene Variant in a Sporadic Case of Multiple Endocrine Neoplasia Type 1

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by the occurrence of hyperparathyroidism, pituitary adenomas and duodeno-pancreatic neuroendocrine tumours (NETs). Germline mutations of the MEN1 gene are identified in up to 87% of MEN1 families and 82% of isolated MEN1 cases.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Iacovazzo D

Authors: Iacovazzo D, Piacentini S, Lugli F, Bianchi A, Gabrovska P,

Keywords: MEN1, mutation, gastric carcinoid,

#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data

Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Ramundo V

Authors: Ramundo V, Marciello F, Modica R, Marotta V, Pizza G,

Keywords: Multiple Endocrine Neoplasia type 1, Lanreotide, Duodeno-pancreatic NETs.,